Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: hillary kapan who wrote (242)	2/6/1998 5:40:00 AM
From: Jongmans	Respond to of 4474

I fully agree with your view. The upward trend in research and development expenses started in the last quarter. First quarter $ 4.257 mln, second quarter $ 4.273 mln, third quarter $ 4.667 mln and last quarter $ 7.090 mln.This increase was,so is stated in the last report, due to research services provided to the Genomics Center and "increased expenses incurred in the Company's regulated gene therapy program, including manufacturing PROCESS development and other ADVANCED preclinical development costs". This sentence is mostly identical to that in the third quarter, with an exception for the words, put, by me, in capitals, which were this time added. Gives this some indication, that we can expect more, and interesting, news in the coming months? Also a milestone-payment for the osteoporosis signal transduction inhibitor program? Martin

To: hillary kapan who wrote (242)	2/9/1998 1:13:00 AM
From: Jongmans	Read Replies (1) \| Respond to of 4474

Lehman's Price Target $ 11 In a report dated 02/05/98 Lehman's analysts CA Butler, PhD/EEnde, MD conclude: " * We suggest that key events for the stock in the near-term will tend to be clinical/regulatory and strategic in nature, and not necessarily financial * We anticipate several major events in the near-term including a partnership in inflammation and the gene therapy programs in 1H98 * We expect IND filings in the gene therapy program in the 1q98 as well as another signaling program in early 1998 * The current technology value of Ariad is $ 51.5 million ( with cash of $ 29.3 million). With a valuation that remains attractive over the longer-term, we reaffirm our V1-Venture rating." Full report on: lehman.com best regards Martin